KRAS G12V | ApexOnco - Clinical Trials news and analysis

x

“The insights provided by the analysts are great”

Andrea Gnirke-Maier

Director New Product Planning

Morphosys

Click here for more information

Data insights

13 December 2024

Another pan-KRAS project enters the clinic

Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.

Subscribe to KRAS G12V